ABCL

AbCellera BiologicsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$7.50

+22.3% vs current

Most likely

Base case

45%

Probability

Target price

$5.20

-15.2% vs current

B-

Bear case

30%

Probability

Target price

$3.00

-51.1% vs current

AI sentiment snapshot

Latest data as of 2026-05-14

AI commentary

Headline tone improved after the May 11, 2026 earnings release because company-reported ABCL635 interim data were directionally supportive, and third-party coverage noted an immediate after-hours gain of about 7.7% on May 11. But by the May 13, 2026 anchor close of $4.77, that initial reaction had largely faded, and no clear delayed analyst target-reset cycle was found, which keeps this in cautious monitoring territory rather than a confirmed sentiment breakout.

RankAlpha Sentiment Codex - 2026-05-14

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-11catalystABCL635 interim Phase 1 data de-risked the program but left the main efficacy test aheadHigh impact

AbCellera reported that interim Phase 1 data for ABCL635 showed robust NK3R target engagement, favorable tolerability, and a pharmacokinetic profile that may support once-monthly dosing, supporting advancement into Phase 2; this improves setup versus the prior baseline, but the decisive efficacy proof point is still the Phase 2 readout rather than the just-reported biomarker data. [#8-K-2026-05-11]

2026-09-30eventQ3 2026 ABCL635 Phase 2 efficacy readout remains the key value inflectionHigh impact

Management said it looks forward to the Phase 2 efficacy readout for ABCL635 in Q3 2026 and framed it as a highly de-risking milestone for the pipeline pivot, making this the main medium-term catalyst after the post-earnings update. [#8-K-2026-05-11]

2026-12-31catalystLiquidity and 2026 pipeline execution can sustain multiple shots on goalHigh impact

AbCellera ended Q1 2026 with about $531 million of cash, cash equivalents, and marketable securities plus roughly $124 million of available non-dilutive government funding, or about $655 million of total available liquidity, while management said 2026 priorities include advancing ABCL688 and ABCL386 through IND-enabling work and selecting at least one additional development candidate. [#8-K-2026-05-11] [#10-Q-2026-05-11]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-14 • Updated nightlySource: Internal modelMethodology